Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Corcept Therapeutics Incorporated (CORT): Are Hedge Funds Right About This Stock?

Page 1 of 2

With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Corcept Therapeutics Incorporated (NASDAQ:CORT).

Corcept Therapeutics Incorporated (NASDAQ:CORT) represented one of the most successful biotech bets in the first half of 2015, as the stock gained more than 100% during this period. This led to an increase in interest from smart money investors and during the third quarter, the number of funds bullish on CORT (among the funds we track) increased by five. However, the level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Multi-Fineline Electronix, Inc. (NASDAQ:MFLX), Catchmark Timber Trust Inc (NYSE:CTT), and Apollo Residential Mortgage Inc (NYSE:AMTG) to gather more data points.

Follow Corcept Therapeutics Inc (NASDAQ:CORT)
Trade (NASDAQ:CORT) Now!

According to most market participants, hedge funds are viewed as underperforming, old investment tools of years past. While there are over an 8000 funds in operation at present, We hone in on the elite of this group, about 700 funds. These money managers command the lion’s share of all hedge funds’ total asset base, and by keeping track of their top picks, Insider Monkey has determined a few investment strategies that have historically outpaced the market. Insider Monkey’s small-cap hedge fund strategy beat the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Keeping this in mind, let’s take a gander at the key action regarding Corcept Therapeutics Incorporated (NASDAQ:CORT).

How have hedgies been trading Corcept Therapeutics Incorporated (NASDAQ:CORT)?

At the Q3’s end, a total of 14 of the hedge funds tracked by Insider Monkey were bullish on this stock. Among these funds, Jim Simons’ Renaissance Technologies has the most valuable position in Corcept Therapeutics Incorporated (NASDAQ:CORT), worth close to $1.7 million, comprising less than 0.1% of its total 13F portfolio. The second largest stake is held by Millennium Management, led by Israel Englander, holding a $1.2 million position; less than 0.1%% of its 13F portfolio is allocated to the stock. Remaining hedge funds and institutional investors that hold long positions include John Overdeck and David Siegel’s Two Sigma Advisors, Cliff Asness’ AQR Capital Management, and Ken Griffin’s Citadel Investment Group.

Page 1 of 2
Loading Comments...